You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethotrexate
Accession NumberDB00563  (APRD00353)
TypeSmall Molecule
GroupsApproved
Description

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. [PubChem]

Structure
Thumb
Synonyms
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Amethopterin
Emtexate
Ledertrexate
Methotrexat
Méthotrexate
Methotrexatum
Metotrexato
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Jamp-methotrexatesolution25 mgintra-arterial; intramuscular; intrathecal; intravenousJamp Pharma Corporation2014-03-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexatetablet2.5 mg/1oralMajor Pharmaceuticals2009-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatesolution25 mgintra-arterial; intramuscular; intravenousPfizer Canada Inc1997-01-242011-05-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexatetablet2.5 mg/1oralPd Rx Pharmaceuticals, Inc.1953-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralDAVA Pharmaceuticals, Inc.1953-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralDispensing Solutions, Inc.1953-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mgoralPfizer Canada Inc1996-11-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexatetablet2.5 mg/1oralREMEDYREPACK INC.2015-09-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousHospira Worldwide, Inc.1959-08-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intravenousHospira Worldwide, Inc.1959-08-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralRebel Distributors Corp1953-12-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Dbl Inj 10mg/mlliquid10 mgintravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Dbl Inj 2.5mg/mlliquid2.5 mgintravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311998-08-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Dbl Inj 25mg/mlliquid25 mgintravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311998-08-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection BPsolution25 mgintra-arterial; intramuscular; intrathecal; intravenousUman Pharma IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection USPsolution25 mgintra-arterial; intramuscular; intravenousSandoz Canada Incorporated2013-02-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, BPsolution25 mgintra-arterial; intramuscular; intrathecal; intravenousPharmascience Inc2014-05-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, BPsolution25 mgintra-arterial; intramuscular; intrathecal; intravenousAccord Healthcare Inc2011-09-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, BPsolution20 mgintra-arterial; intramuscular; intrathecal; intravenousPharmascience Inc2014-05-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, BPsolution15 mgintra-arterial; intramuscular; intrathecal; intravenousPharmascience Inc2014-05-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, BPsolution10 mgintra-arterial; intramuscular; intrathecal; intravenousPharmascience Inc2014-05-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, BPsolution7.5 mgintra-arterial; intramuscular; intrathecal; intravenousPharmascience Inc2014-05-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, USPsolution25 mgintravenousHospira Healthcare Corporation1997-07-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, USPsolution25 mgintra-arterial; intramuscular; intrathecal; intravenousMylan Pharmaceuticals Ulc2014-08-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, USPsolution25 mgintra-arterial; intramuscular; intrathecal; intravenousHospira Healthcare Corporation1998-07-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, USPsolution10 mgintra-arterial; intramuscular; intrathecal; intravenousHospira Healthcare Corporation1997-07-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Injection, USPsolution25 mgintra-arterial; intramuscular; intravenousHospira Healthcare Corporation1998-04-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate PF/sa Injectionsolution25 mgintra-arterial; intramuscular; intrathecal; intravenousSandoz Canada IncorporatedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Sod Inj 25mg/ml USPliquid25 mgintra-arterial; intramuscular; intrathecal; intravenousDavid Bull Laboratories (Pty) Ltd.1990-12-311998-08-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Sodiumtablet2.5 mg/1oralGen Pak Solutions Llc2012-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodium Inj 20mgpowder for solution20 mgintramuscular; intrathecal; intravenousLederle Cyanamid Canada Inc.1977-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Sodium Inj 25.0mg/mlliquid25 mgintramuscular; intrathecal; intravenousLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Sodium Inj 25mg/mlliquid50 mgintramuscular; intrathecal; intravenousLederle Cyanamid Canada Inc.1981-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Sodium Inj 25mg/ml USPliquid25 mgintra-arterial; intramuscular; intrathecal; intravenousDavid Bull Laboratories (Pty) Ltd.1992-12-311999-08-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Sodium Injectionsolution25 mgintra-arterial; intramuscular; intrathecal; intravenousTeva Canada Limited1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Sodium Injection USPsolution25 mgintra-arterial; intramuscular; intrathecal; intravenous; intraventricularPfizer Canada Inc1996-09-052006-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Tab 2.5mgtablet2.5 mgoralLederle Cyanamid Canada Inc.1955-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Tab 2.5mg USPtablet2.5 mgoralDavid Bull Laboratories (Pty) Ltd.1991-12-312000-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate Tablets, USPtablet10 mgoralHospira Healthcare Corporation2004-04-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate-liq Im IV Iar Int Ivr 25mg/mlliquid25 mgintra-arterial; intramuscular; intrathecal; intravenousWyeth Ayerst Canada Inc.1997-02-042001-09-19Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexate-pws Im IV Iar Int Ivr 20mg/vialpowder for solution20 mgintra-arterial; intramuscular; intrathecal; intravenousWyeth Ayerst Canada Inc.1997-02-042001-05-22Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Metojectsolution7.5 mgintra-arterial; intramuscular; intravenousMedexus Inc2009-01-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Metojectsolution25 mgintra-arterial; intramuscular; intravenousMedexus Inc2009-01-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Metojectsolution15 mgintra-arterial; intramuscular; intravenousMedexus Inc2009-01-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Metojectsolution20 mgintra-arterial; intramuscular; intravenousMedexus Inc2008-05-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Metojectsolution10 mgintra-arterial; intramuscular; intravenousMedexus Inc2009-01-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Otrexupinjection, solution7.5 mg/.4mLsubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Otrexupinjection, solution25 mg/.4mLsubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Otrexupinjection, solution20 mg/.4mLsubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Otrexupinjection, solution15 mg/.4mLsubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Otrexupinjection, solution10 mg/.4mLsubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution30 mg/.6mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution22.5 mg/.45mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution20 mg/.4mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution17.5 mg/.35mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution15 mg/.3mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution12.5 mg/.25mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution10 mg/.2mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution27.5 mg/.55mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution7.5 mg/.15mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rasuvoinjection, solution25 mg/.5mLsubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Ratio-methotrexate Sodiumtablet2.5 mgoralTeva Canada Limited2001-11-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rheumatrex Dose Packtablet2.5 mg/1oralDAVA Pharmaceuticals, Inc.1953-07-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rheumatrex Tab 2.5mgtablet2.5 mgoralLederle Cyanamid Canada Inc.1990-12-312000-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rheumatrex-tab 2.5mgtablet2.5 mgoralWyeth Ayerst Canada Inc.1999-04-122000-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-methotrexatetablet2.5 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-methotrexatetablet2.5 mgoralHospira Healthcare Corporation1999-09-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousMylan Institutional LLC2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralMylan Institutional Inc.1995-07-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousFresenius Kabi USA, LLC2003-04-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousTeva Parenteral Medicines, Inc.2012-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralPd Rx Pharmaceuticals, Inc.1990-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousTeva Parenteral Medicines, Inc.2012-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution1 g/40mLintra-arterial; intramuscular; intrathecal; intravenousMylan Institutional LLC2012-06-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralAv Kare, Inc.2014-11-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousPhysicians Total Care, Inc.2003-03-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousTeva Parenteral Medicines, Inc.2012-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralRebel Distributors Corp1990-10-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousAccord Healthcare, Inc.2014-02-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousTeva Parenteral Medicines, Inc.2012-08-012016-01-22Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousMylan Institutional LLC2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, solution25 mg/mLintra-arterial; intramuscular; intravenousFresenius Kabi USA, LLC2001-09-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralBarr Laboratories Inc.1990-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousMylan Institutional LLC2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousMylan Institutional LLC2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection, powder, lyophilized, for solution1 g/1intra-arterial; intramuscular; intrathecal; intravenousFresenius Kabi USA, LLC2000-01-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexatetablet2.5 mg/1oralMylan Pharmaceuticals Inc.1992-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexateinjection25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousMylan Institutional LLC2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiumtablet2.5 mg/1oralRoxane Laboratories, Inc1994-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiuminjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiuminjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousMylan Institutional LLC2012-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiumtablet2.5 mg/1oralPhysicians Total Care, Inc.2007-12-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiuminjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousSandoz Inc2009-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiuminjection, solution25 mg/mLintra-arterial; intramuscular; intrathecal; intravenousSandoz Inc2009-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiumtablet2.5 mg/1oralbryant ranch prepack1994-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiumtablet2.5 mg/1oralREMEDYREPACK INC.2011-07-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiumtablet2.5 mg/1oralRoxane Laboratories, Inc1994-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Methotrexate Sodiumtablet2.5 mg/1oralREMEDYREPACK INC.2011-06-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Trexalltablet, film coated15 mg/1oralTeva Women's Health, Inc.2001-05-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Trexalltablet, film coated10 mg/1oralTeva Women's Health, Inc.2001-05-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Trexalltablet, film coated7.5 mg/1oralTeva Women's Health, Inc.2001-05-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Trexalltablet, film coated5 mg/1oralTeva Women's Health, Inc.2001-05-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AbitrexateTeva
AlltrexNaprod
ArtraitTRB
AtrexelSchering-Plough
BendatrexatBendalis
CarditrexCadila
DermotrexEast West
EbetrexEbewe
EmtexateNot Available
LedertrexateBiodim
MaxtrexPfizer
MeisushengHospira
MexateCadila HC
RheumatrexWyeth KK
TrexanAtafarm
ZexateDabur Pharma
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methotrexate Sodium
Thumb
  • InChI Key: DASQOOZCTWOQPA-GXKRWWSZSA-L
  • Monoisotopic Mass: 498.13520514
  • Average Mass: 498.4029
DBSALT000115
Categories
UNIIYL5FZ2Y5U1
CAS number59-05-2
WeightAverage: 454.4393
Monoisotopic: 454.171315854
Chemical FormulaC20H22N8O5
InChI KeyInChIKey=FBOZXECLQNJBKD-ZDUSSCGKSA-N
InChI
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
IUPAC Name
(2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid
SMILES
CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as folic acids. These are heterocyclic compounds based on the 4-[(pteridin-6-ylmethyl)amino]benzoic acid skeleton conjugated with one or more L-glutamate units.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPteridines and derivatives
Sub ClassPterins and derivatives
Direct ParentFolic acids
Alternative Parents
Substituents
  • Folic acid
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Hippuric acid
  • Hippuric acid or derivatives
  • Aminobenzoic acid or derivatives
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Benzoic acid or derivatives
  • Benzamide
  • Aminobenzamide
  • Substituted aniline
  • Dialkylarylamine
  • Benzoyl
  • Aralkylamine
  • Aniline
  • Aminopyrimidine
  • Amino fatty acid
  • Fatty acyl
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Pyrazine
  • Primary aromatic amine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationMethotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis.
PharmacodynamicsMethotrexate is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Methotrexate inhibits folic acid reductase which is responsible for the conversion of folic acid to tetrahydrofolic acid. At two stages in the biosynthesis of purines and at one stage in the synthesis of pyrimidines, one-carbon transfer reactions occur which require specific coenzymes synthesized in the cell from tetrahydrofolic acid. Tetrahydrofolic acid itself is synthesized in the cell from folic acid with the help of an enzyme, folic acid reductase. Methotrexate looks a lot like folic acid to the enzyme, so it binds to it quite strongly and inhibits the enzyme. Thus, DNA synthesis cannot proceed because the coenzymes needed for one-carbon transfer reactions are not produced from tetrahydrofolic acid because there is no tetrahydrofolic acid. Methotrexate selectively affects the most rapidly dividing cells (neoplastic and psoriatic cells). Methotrexate is also indicated in the management of severe, active, classical, or definite rheumatoid arthritis.
Mechanism of actionMethotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known.
AbsorptionOral absorption is dose dependent in adults and leukemic pediatric patients. In adults, peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of 60%. At doses greater than 80 mg/m^2, the absorption of the doses is significantly less due to a saturation effect.
Volume of distribution
  • 0.18 L/kg [initial volume of distribution (Vd)]
  • 0.4 – 0.8 L/kg [steady state Vd]
    Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate does not cross the blood-brain-barrier.
Protein binding50% bound to protein, primarily to albumin
Metabolism

Methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydroxylase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate synthetase. A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. Furthermore, intestinal flora partially metabolizes methotrexate after oral administration.

SubstrateEnzymesProduct
Methotrexate
7-hydroxymethotrexateDetails
Route of eliminationRenal excretion is the primary route of elimination and is dependent upon dosage and route of administration. IV administration, 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose.
Half lifeLow doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.
Clearance

Methotrexate clearance rates vary widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity.

ToxicitySymptoms of overdose include bone marrow suppression and gastrointestinal toxicity. LD50=43mg/kg(orally in rat).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Canalicular multispecific organic anion transporter 1
Gene symbol: ABCC2
UniProt: Q92887
Not AvailableABCC2 IVS 23+56T alleleGeneral toxicity (gastrointestinal and hepatotoxicity)18381794
Methylenetetrahydrofolate reductase
Gene symbol: MTHFR
UniProt: P42898
rs1801133 Not AvailableT alleleMucositis, hepatic toxicity, thrombocytopenia, alopecia17488658
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8261
Blood Brain Barrier-0.9467
Caco-2 permeable-0.7754
P-glycoprotein substrateSubstrate0.8172
P-glycoprotein inhibitor INon-inhibitor0.7752
P-glycoprotein inhibitor IINon-inhibitor0.9879
Renal organic cation transporterNon-inhibitor0.8886
CYP450 2C9 substrateNon-substrate0.85
CYP450 2D6 substrateNon-substrate0.7968
CYP450 3A4 substrateSubstrate0.5177
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9739
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9517
BiodegradationNot ready biodegradable0.9741
Rat acute toxicity3.4955 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9564
hERG inhibition (predictor II)Non-inhibitor0.6958
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abic ltd
  • Pharmacia and upjohn co
  • Hospira inc
  • App pharmaceuticals llc
  • Abraxis pharmaceutical products
  • Bedford laboratories div ben venue laboratories inc
  • Norbrook laboratories ltd
  • Pharmachemie usa inc
  • Bioniche pharma usa llc
  • Ebewe pharma ges mbh nfg kg
  • Pharmachemie bv
  • Bristol laboratories inc div bristol myers co
  • Bristol myers co
  • Bristol myers squibb
  • Barr laboratories inc
  • Dava pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injectionintra-arterial; intramuscular; intrathecal; intravenous25 mg/mL
Injection, powder, lyophilized, for solutionintra-arterial; intramuscular; intrathecal; intravenous1 g/1
Injection, solutionintra-arterial; intramuscular; intrathecal; intravenous1 g/40mL
Injection, solutionintra-arterial; intramuscular; intravenous25 mg/mL
Tabletoral2.5 mg
Liquidintravenous10 mg
Liquidintravenous2.5 mg
Liquidintravenous25 mg
Solutionintra-arterial; intramuscular; intrathecal; intravenous15 mg
Solutionintra-arterial; intramuscular; intrathecal; intravenous20 mg
Solutionintra-arterial; intramuscular; intrathecal; intravenous7.5 mg
Solutionintra-arterial; intramuscular; intrathecal; intravenous10 mg
Solutionintra-arterial; intramuscular; intravenous25 mg
Solutionintravenous25 mg
Injection, solutionintra-arterial; intramuscular; intrathecal; intravenous25 mg/mL
Tabletoral2.5 mg/1
Powder for solutionintramuscular; intrathecal; intravenous20 mg
Liquidintramuscular; intrathecal; intravenous25 mg
Liquidintramuscular; intrathecal; intravenous50 mg
Liquidintra-arterial; intramuscular; intrathecal; intravenous25 mg
Solutionintra-arterial; intramuscular; intrathecal; intravenous25 mg
Solutionintra-arterial; intramuscular; intrathecal; intravenous; intraventricular25 mg
Tabletoral10 mg
Powder for solutionintra-arterial; intramuscular; intrathecal; intravenous20 mg
Solutionintra-arterial; intramuscular; intravenous10 mg
Solutionintra-arterial; intramuscular; intravenous15 mg
Solutionintra-arterial; intramuscular; intravenous20 mg
Solutionintra-arterial; intramuscular; intravenous7.5 mg
Injection, solutionsubcutaneous10 mg/.4mL
Injection, solutionsubcutaneous15 mg/.4mL
Injection, solutionsubcutaneous20 mg/.4mL
Injection, solutionsubcutaneous25 mg/.4mL
Injection, solutionsubcutaneous7.5 mg/.4mL
Injection, solutionsubcutaneous10 mg/.2mL
Injection, solutionsubcutaneous12.5 mg/.25mL
Injection, solutionsubcutaneous15 mg/.3mL
Injection, solutionsubcutaneous17.5 mg/.35mL
Injection, solutionsubcutaneous22.5 mg/.45mL
Injection, solutionsubcutaneous25 mg/.5mL
Injection, solutionsubcutaneous27.5 mg/.55mL
Injection, solutionsubcutaneous30 mg/.6mL
Injection, solutionsubcutaneous7.5 mg/.15mL
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral5 mg/1
Tablet, film coatedoral7.5 mg/1
Prices
Unit descriptionCostUnit
Methotrexate powder261.33USD g
Rheumatrex 8 2.5 mg tablet Disp Pack169.98USD disp
Rheumatrex 24 2.5 mg tablet Disp Pack129.06USD disp
Rheumatrex 20 2.5 mg tablet Disp Pack107.59USD disp
Rheumatrex 12 2.5 mg tablet Disp Pack63.65USD disp
Methotrexate Sodium 25 mg/ml (pf) Solution 40ml Vial58.99USD vial
Trexall 15 mg tablet25.98USD tablet
Methotrexate Sodium 25 mg/ml (pf) Solution 10ml Vial24.99USD vial
Trexall 10 mg tablet17.67USD tablet
Methotrexate Sodium 25 mg/ml Solution 1 Vial = 2ml15.11USD vial
Methotrexate Sodium 25 mg/ml (pf) Solution 2ml Vial14.99USD vial
Trexall 7.5 mg tablet12.99USD tablet
Rheumatrex 2.5 mg tablet11.23USD tablet
Trexall 5 mg tablet8.66USD tablet
Methotrexate Sod. (Preserved) 25 mg/ml8.38USD ml
Methotrexate Sod.(Unpreserved) 25 mg/ml4.56USD ml
Methotrexate 2.5 mg tablet2.71USD tablet
Methotrexate 10 mg Tablet2.58USD tablet
Ratio-Methotrexate Sodium 2.5 mg Tablet0.66USD tablet
Apo-Methotrexate 2.5 mg Tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195 °CNot Available
water solubility2600 mg/LNot Available
logP-1.85HANSCH,C ET AL. (1995)
Caco2 permeability-5.92ADME Research, USCD
pKa4.7SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP-0.91ALOGPS
logP-0.5ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)2.81ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area210.54 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity119.21 m3·mol-1ChemAxon
Polarizability44.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-qz10000000-25b0e287457fb3845ef4View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

DrugSyn.org

US2512572
General References
  1. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81. Pubmed
  2. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005 Feb;114(2):154-63. Pubmed
External Links
ATC CodesL01BA01L04AX03
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (518 KB)
MSDSDownload (77 KB)
Interactions
Drug Interactions
Drug
Acetylsalicylic acidThe serum concentration of Methotrexate can be increased when it is combined with Acetylsalicylic acid.
AcitretinAcitretin may increase the hepatotoxic activities of Methotrexate.
AlitretinoinAlitretinoin may increase the hepatotoxic activities of Methotrexate.
AmdinocillinThe serum concentration of Methotrexate can be increased when it is combined with Amdinocillin.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Methotrexate.
Aminosalicylic AcidThe serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic Acid.
AmoxicillinThe serum concentration of Methotrexate can be increased when it is combined with Amoxicillin.
AmpicillinThe serum concentration of Methotrexate can be increased when it is combined with Ampicillin.
AzidocillinThe serum concentration of Methotrexate can be increased when it is combined with Azidocillin.
AzlocillinThe serum concentration of Methotrexate can be increased when it is combined with Azlocillin.
BacampicillinThe serum concentration of Methotrexate can be increased when it is combined with Bacampicillin.
Benzathine benzylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Benzathine benzylpenicillin.
BenzylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Benzylpenicillin.
Bismuth SubsalicylateThe serum concentration of Methotrexate can be increased when it is combined with Bismuth Subsalicylate.
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate.
CarbenicillinThe serum concentration of Methotrexate can be increased when it is combined with Carbenicillin.
CelecoxibThe serum concentration of Methotrexate can be increased when it is combined with Celecoxib.
CholestyramineCholestyramine can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinThe serum concentration of Methotrexate can be increased when it is combined with Ciprofloxacin.
CloxacillinThe serum concentration of Methotrexate can be increased when it is combined with Cloxacillin.
ClozapineThe risk or severity of adverse effects can be increased when Methotrexate is combined with Clozapine.
ColesevelamColesevelam can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclacillinThe serum concentration of Methotrexate can be increased when it is combined with Cyclacillin.
CyclosporineThe serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Methotrexate.
DexketoprofenThe serum concentration of Methotrexate can be increased when it is combined with Dexketoprofen.
DiclofenacThe serum concentration of Methotrexate can be increased when it is combined with Diclofenac.
DicloxacillinThe serum concentration of Methotrexate can be increased when it is combined with Dicloxacillin.
DiflunisalThe serum concentration of Methotrexate can be increased when it is combined with Diflunisal.
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Methotrexate.
EltrombopagThe serum concentration of Methotrexate can be increased when it is combined with Eltrombopag.
EsomeprazoleThe serum concentration of Methotrexate can be increased when it is combined with Esomeprazole.
Ethacrynic acidThe therapeutic efficacy of Ethacrynic acid can be decreased when used in combination with Methotrexate.
EtodolacThe serum concentration of Methotrexate can be increased when it is combined with Etodolac.
FenoprofenThe serum concentration of Methotrexate can be increased when it is combined with Fenoprofen.
FloctafenineThe serum concentration of Methotrexate can be increased when it is combined with Floctafenine.
FlucloxacillinThe serum concentration of Methotrexate can be increased when it is combined with Flucloxacillin.
FlurbiprofenThe serum concentration of Methotrexate can be increased when it is combined with Flurbiprofen.
FoscarnetFoscarnet may increase the nephrotoxic activities of Methotrexate.
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Methotrexate.
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methotrexate.
HetacillinThe serum concentration of Methotrexate can be increased when it is combined with Hetacillin.
IbuprofenThe serum concentration of Methotrexate can be increased when it is combined with Ibuprofen.
IndomethacinThe serum concentration of Methotrexate can be increased when it is combined with Indomethacin.
InfliximabThe serum concentration of Methotrexate can be increased when it is combined with Infliximab.
KetoprofenThe serum concentration of Methotrexate can be increased when it is combined with Ketoprofen.
KetorolacThe serum concentration of Methotrexate can be increased when it is combined with Ketorolac.
LansoprazoleThe serum concentration of Methotrexate can be increased when it is combined with Lansoprazole.
LeflunomideThe risk or severity of adverse effects can be increased when Methotrexate is combined with Leflunomide.
LumacaftorThe serum concentration of Methotrexate can be decreased when it is combined with Lumacaftor.
Magnesium salicylateThe serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate.
Mefenamic acidThe serum concentration of Methotrexate can be increased when it is combined with Mefenamic acid.
MeloxicamThe serum concentration of Methotrexate can be increased when it is combined with Meloxicam.
MetamizoleThe risk or severity of adverse effects can be increased when Methotrexate is combined with Metamizole.
MeticillinThe serum concentration of Methotrexate can be increased when it is combined with Meticillin.
MezlocillinThe serum concentration of Methotrexate can be increased when it is combined with Mezlocillin.
MipomersenMipomersen may increase the hepatotoxic activities of Methotrexate.
NabumetoneThe serum concentration of Methotrexate can be increased when it is combined with Nabumetone.
NafcillinThe serum concentration of Methotrexate can be increased when it is combined with Nafcillin.
NaproxenThe serum concentration of Methotrexate can be increased when it is combined with Naproxen.
NatalizumabThe risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.
OmeprazoleThe serum concentration of Methotrexate can be increased when it is combined with Omeprazole.
OxacillinThe serum concentration of Methotrexate can be increased when it is combined with Oxacillin.
OxaprozinThe serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.
PantoprazoleThe serum concentration of Methotrexate can be increased when it is combined with Pantoprazole.
PhenoxymethylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Phenoxymethylpenicillin.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Methotrexate.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methotrexate.
PiperacillinThe serum concentration of Methotrexate can be increased when it is combined with Piperacillin.
PiroxicamThe serum concentration of Methotrexate can be increased when it is combined with Piroxicam.
PivampicillinThe serum concentration of Methotrexate can be increased when it is combined with Pivampicillin.
PivmecillinamThe serum concentration of Methotrexate can be increased when it is combined with Pivmecillinam.
ProbenecidThe serum concentration of Methotrexate can be increased when it is combined with Probenecid.
Procaine benzylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Procaine benzylpenicillin.
RabeprazoleThe serum concentration of Methotrexate can be increased when it is combined with Rabeprazole.
RanolazineThe serum concentration of Methotrexate can be increased when it is combined with Ranolazine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Methotrexate.
RolapitantThe serum concentration of Methotrexate can be increased when it is combined with Rolapitant.
Salicylate-sodiumThe serum concentration of Methotrexate can be increased when it is combined with Salicylate-sodium.
SalsalateThe serum concentration of Methotrexate can be increased when it is combined with Salsalate.
SaquinavirThe serum concentration of Methotrexate can be increased when it is combined with Saquinavir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methotrexate.
SulfadiazineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Methotrexate.
SulfasalazineSulfasalazine may increase the hepatotoxic activities of Methotrexate.
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Methotrexate.
SulindacThe serum concentration of Methotrexate can be increased when it is combined with Sulindac.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Methotrexate.
TegafurThe risk or severity of adverse effects can be increased when Methotrexate is combined with Tegafur.
TeriflunomideThe serum concentration of Methotrexate can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Methotrexate can be decreased when it is combined with Tesmilifene.
TetrahydrobiopterinThe serum concentration of Tetrahydrobiopterin can be decreased when it is combined with Methotrexate.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Methotrexate.
Tiaprofenic acidThe serum concentration of Methotrexate can be increased when it is combined with Tiaprofenic acid.
TicarcillinThe serum concentration of Methotrexate can be increased when it is combined with Ticarcillin.
TofacitinibMethotrexate may increase the immunosuppressive activities of Tofacitinib.
TolmetinThe serum concentration of Methotrexate can be increased when it is combined with Tolmetin.
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.
TrastuzumabTrastuzumab may increase the neutropenic activities of Methotrexate.
TrimethoprimThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Methotrexate.
VerapamilThe serum concentration of Methotrexate can be increased when it is combined with Verapamil.
Food Interactions
  • Milk appears to reduce its absorption.
  • Take without regard to meals. Limit caffeine intake.

Targets

1. Dihydrofolate reductase

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Dihydrofolate reductase P00374 Details

References:

  1. Al-Rashood ST, Aboldahab IA, Nagi MN, Abouzeid LA, Abdel-Aziz AA, Abdel-Hamide SG, Youssef KM, Al-Obaid AM, El-Subbagh HI: Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg Med Chem. 2006 Dec 15;14(24):8608-21. Epub 2006 Sep 12. Pubmed
  2. Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007 Mar;26(1):153-81. Pubmed
  3. Bennett B, Langan P, Coates L, Mustyakimov M, Schoenborn B, Howell EE, Dealwis C: Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate. Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18493-8. Epub 2006 Nov 27. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  5. Totani K, Matsuo I, Ihara Y, Ito Y: High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates. Bioorg Med Chem. 2006 Aug 1;14(15):5220-9. Epub 2006 May 2. Pubmed
  6. Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, Handa H: A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol. 2006 Nov;70(5):1832-9. Epub 2006 Aug 25. Pubmed

Enzymes

1. Aldehyde oxidase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Aldehyde oxidase Q06278 Details

References:

  1. Zientek M, Jiang Y, Youdim K, Obach RS: In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos. 2010 Aug;38(8):1322-7. Epub 2010 May 5. Pubmed
  2. Baggott JE, Morgan SL: Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum. 2009 Aug;60(8):2257-61. Pubmed
  3. Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C: Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol. 1999 Apr;51(4):411-8. Pubmed

2. Methylenetetrahydrofolate reductase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Methylenetetrahydrofolate reductase P42898 Details

References:

  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. Pubmed
  2. Kremer JM: Methotrexate pharmacogenomics. Ann Rheum Dis. 2006 Sep;65(9):1121-3. Pubmed

3. 6-phosphogluconate dehydrogenase, decarboxylating

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
6-phosphogluconate dehydrogenase, decarboxylating P52209 Details

References:

  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Mar 17. Pubmed
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

4. Folylpolyglutamate synthase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Folylpolyglutamate synthase, mitochondrial Q05932 Details

References:

  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. Pubmed

5. Gamma-glutamyl hydrolase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Gamma-glutamyl hydrolase Q92820 Details

References:

  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. Pubmed

6. Dihydrofolate reductase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Dihydrofolate reductase P00374 Details

References:

  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. Pubmed

7. Thymidylate synthase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Thymidylate synthase P04818 Details

References:

  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. Pubmed

8. Bifunctional purine biosynthesis protein PURH

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Bifunctional purine biosynthesis protein PURH P31939 Details

References:

  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. Pubmed

Carriers

1. Serum albumin

Kind: Protein

Organism: Human

Pharmacological action: no

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Warnecke A, Fichtner I, Sass G, Kratz F: Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm (Weinheim). 2007 Aug;340(8):389-95. Pubmed
  2. Xie WJ, Feng YP, Cao SL, Zhao YF: [Study of the interaction between methotrexate and bovine serum albumin by spectrometry] Guang Pu Xue Yu Guang Pu Fen Xi. 2006 Oct;26(10):1876-9. Pubmed

Transporters

1. Canalicular multispecific organic anion transporter 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 2 O15438 Details

References:

  1. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y: Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res. 2002 Jan;19(1):34-41. Pubmed
  2. Oleschuk CJ, Deeley RG, Cole SP: Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. Am J Physiol Gastrointest Liver Physiol. 2003 Feb;284(2):G280-9. Epub 2002 Oct 9. Pubmed
  3. Hirohashi T, Suzuki H, Sugiyama Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999 May 21;274(21):15181-5. Pubmed
  4. Zeng H, Liu G, Rea PA, Kruh GD: Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000 Sep 1;60(17):4779-84. Pubmed
  5. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. Pubmed
  6. Paumi CM, Wright M, Townsend AJ, Morrow CS: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. Pubmed
  7. Li T, Ito K, Horie T: Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G602-10. Pubmed
  8. Zehnpfennig B, Urbatsch IL, Galla HJ: Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30. Pubmed

2. Multidrug resistance-associated protein 4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 4 O15439 Details

References:

  1. Chen ZS, Lee K, Kruh GD: Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001 Sep 7;276(36):33747-54. Epub 2001 Jul 10. Pubmed
  2. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. Pubmed
  3. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. Pubmed
  4. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. Pubmed

3. Multidrug resistance-associated protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 1 P33527 Details

References:

  1. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. Pubmed
  2. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. Pubmed
  3. Paumi CM, Wright M, Townsend AJ, Morrow CS: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. Pubmed

4. Solute carrier family 22 member 6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. Pubmed
  2. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. Pubmed
  3. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. Pubmed
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. Pubmed
  5. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. Pubmed
  6. Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. Pubmed

5. Multidrug resistance-associated protein 7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance-associated protein 7 Q5T3U5 Details

References:

  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. Pubmed

6. Solute carrier family 22 member 8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 8 Q8TCC7 Details

References:

  1. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. Pubmed
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. Pubmed
  3. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. Pubmed
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. Pubmed
  5. Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. Pubmed

7. Canalicular multispecific organic anion transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 1 Q92887 Details

References:

  1. Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y: Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Pharm Res. 2001 May;18(5):579-86. Pubmed
  2. Masuda M, I’izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni’inuma K, Suzuki H, Sugiyama Y: Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 1997 Aug 15;57(16):3506-10. Pubmed
  3. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5. Pubmed
  4. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. Pubmed
  5. Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, Liu X: Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm Res. 2003 Jan;20(1):31-7. Pubmed

8. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J, Kwan E, Stewart BW, Mechetner EB, Gudkov AV, Roninson IB: Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer. 1996 Mar 1;65(5):613-9. Pubmed

9. Solute carrier organic anion transporter family member 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1A2 P46721 Details

References:

  1. Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, Hagenbuch B: Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95. Pubmed

10. Monocarboxylate transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Monocarboxylate transporter 1 P53985 Details

References:

  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. Pubmed

11. ATP-binding cassette sub-family C member 11

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
ATP-binding cassette sub-family C member 11 Q96J66 Details

References:

  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. Pubmed

12. Solute carrier organic anion transporter family member 1B3

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1B3 Q9NPD5 Details

References:

  1. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. Pubmed

13. Solute carrier family 22 member 11

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 22 member 11 Q9NSA0 Details

References:

  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. Pubmed

14. Solute carrier organic anion transporter family member 1C1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1C1 Q9NYB5 Details

References:

  1. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. Pubmed

15. Solute carrier organic anion transporter family member 3A1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 3A1 Q9UIG8 Details

References:

  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. Pubmed

16. ATP-binding cassette sub-family G member 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
ATP-binding cassette sub-family G member 2 Q9UNQ0 Details

References:

  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. Pubmed
  2. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. Pubmed
  3. Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J. 2003 Aug 1;373(Pt 3):767-74. Pubmed
  4. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54. Pubmed
  5. Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43. Pubmed
  6. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. Epub 2008 Nov 17. Pubmed
  7. Hou YX, Li CZ, Palaniyandi K, Magtibay PM, Homolya L, Sarkadi B, Chang XB: Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport. Biochemistry. 2009 Sep 29;48(38):9122-31. Pubmed
  8. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11. Pubmed
  9. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. Epub 2009 Feb 18. Pubmed

17. Solute carrier family 22 member 7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 22 member 7 Q9Y694 Details

References:

  1. Sun W, Wu RR, van Poelje PD, Erion MD: Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun. 2001 May 4;283(2):417-22. Pubmed
  2. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. Pubmed

18. Solute carrier organic anion transporter family member 1B1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1B1 Q9Y6L6 Details

References:

  1. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. Pubmed
  2. van de Steeg E, van der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH: Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos. 2009 Feb;37(2):277-81. Epub 2008 Nov 20. Pubmed

19. Proton-coupled folate transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Proton-coupled folate transporter Q96NT5 Details

References:

  1. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. Epub 2007 May 2. Pubmed

20. Solute carrier organic anion transporter family member 4C1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 4C1 Q6ZQN7 Details

References:

  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. Pubmed

21. Folate transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Folate transporter 1 P41440 Details

References:

  1. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID: Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006 Dec 1;127(5):917-28. Pubmed

22. Folate receptor alpha

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Folate receptor alpha P15328 Details

References:

  1. Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, Grover R, Arya V, Dhir V, Gupta R, Kumar U, Juyal RC, B K T: Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics. 2008 Dec;18(12):1041-9. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 08, 2013 14:24